Barriers and facilitators of clinical trial enrollment in a network of community‐based pediatric oncology clinics. Issue 4 (25th September 2019)

• Record Type: Journal Article
• Authors: Russo, Carolyn; Stout, Linda; House, Toni; Santana, Victor M.
• Is Part Of: Pediatric blood & cancer. Volume 67:Issue 4(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2019-09-25
• Subjects: clinical trials -- disparity -- enrollment; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.28023
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract: Introduction: Major advances in the field of pediatric oncology have resulted from rigorous, prospective clinical oncology research trials. Optimizing access for all children and adolescents to clinical research trials is an important goal. Barriers to clinical trial enrollment are numerous, involving the health care system, research infrastructure, access to care, providers, and participants. The perspectives of pediatric oncologists may provide insight into the barriers of clinical trial enrollment for this unique population. Methods and materials: We conducted qualitative structured interviews over two months of pediatric oncologists in a community‐based clinical network as part of a quality improvement project aimed at increasing enrollment rates at St. Jude Affiliate Clinics. We assessed barriers and facilitators to clinical trial opportunities for racial and ethnic minority pediatric participants. In the same fiscal year of the interviews, we tracked clinical trial enrollment by race and ethnicity of the participant over 12 months. Results: The major barriers to clinical trial enrollment for pediatric cancer minority participants included language discordance, travel difficulties, and complex trial designs. In contrast, the major facilitators included building trust with participants and their parents, and education on the merits of clinical research studies. We did not observe any disparities in clinical trial enrollment among the racial and ethnic minority participants of the clinical trials conducted across our network of pediatric oncology clinics. Conclusions: Identifying barriers and facilitators may improve clinical trial enrollment for underrepresented participant groups.